Os mercados cada vez mais competitivos fazem com que as empresas busquem novas formas organizacionais e desenvolvam "capacidades dinâmicas" a fim de sobreviver no mundo globalizado. Nesse contexto, a inovação se tornou tema central para a competitividade. As fontes de inovação estão cada vez mais diversificadas e dispersas geograficamente, as empresas utilizam fontes internas e externas para o desenvolvimento de soluções inovadoras e modelos de negócios diferenciados. Estudos afirmam, que durante todos os anos, são produzidos milhares de artigos científicos que envolvem a biotecnologia, mostrando que é um dos campos mais promissores do mundo, com implicações importantes para economia global. A biotecnologia é caracterizada por ser baseada na ciência, ser multidisciplinar e o seu desenvolvimento é realizado por meio da interface com diversos atores, sendo altamente dependente do seu ambiente institucional. Assim, dado o contexto da biotecnologia, as lentes da teoria das capacidades dinâmicas são úteis para verificar a construção do conhecimento que conduz ao desenvolvimento de novos produtos, já que as empresas não podem depender somente do desenvolvimento do conhecimento interno, elas devem absorver conhecimentos relevantes de fontes externas. No setor de biotecnologia...
This paper offers an overview of the origin, evolution and main features of the biotechnology industry, putting particular emphasis on the behaviour of one key actor – the dedicated biotechnology firm. It starts with a brief historical background detailing the origin and dynamics of the industry, which is followed by a more detailed examination of the firms’ strategies, business models and networking behaviour. It concludes with a discussion on the constraints and opportunities faced by firms operating outside the main centres of knowledge production and business in biotechnology, as is the case of dedicated biotechnology firms located in Portugal.
Dissertação de mest., Economia da Inovação e do Empreendedorismo, Faculdade de Economia, Univ. do Algarve, 2010; Facing the world scenario, businesses are striving for efficiency and profitability.
The processes of innovation, learning, and experience accumulation are, indeed,
thought to be crucial for sustaining competitiveness of businesses. The experience
curve concept integrates those processes, as it is based on the premise that the
more often a task is performed, the lower will be the cost of doing it.
Although extensive research has shown that cumulative experience leads to
performance improvement, across numerous sectors, our work fills part of the
existing knowledge gap by focusing on experience curve and learning aspects of
the modern biotechnology of Microalgae Production Systems (MPS). Microalgae
are one of the most exciting future-oriented business areas of modern
biotechnologies, which have turned into an important global industry, with a
diversified field of applications.
The particularities of learning and experience accumulation processes were
introduced in our work. Our study also addressed some of the applications and
misapplications of the experience curve concept. We also reported on some of the
perspectives and advances of the MPS...
The World Antibody-Drug Conjugate (WADC) Summits organized by Hanson Wade are currently the largest meetings fully dedicated to ADCs. The first global ADC Summit was organized in Boston in October 2010. Since 2011, two WADC are held every year in Frankfurt and San Francisco, respectively. The 2013 WADC San Francisco event was structured around plenary sessions with keynote speakers from AbbVie, Agensys, ImmunoGen, Immunomedics, Genentech, Pfizer and Seattle Genetics. Parallel tracks were also organized addressing ADC discovery, development and optimization of chemistry, manufacturing and control (CMC) issues. Discovery and process scientists, regulatory experts (US Food and Drug Administration), academics and clinicians were present, including representatives from biotechnology firms (Concortis, CytomX Therapeutics, Glykos, Evonik, Igenica, Innate Pharma, Mersana Therapeutics, Polytherics, Quanta Biodesign, Redwood Bioscience, Sutro Biopharma, SynAffix), pharmaceutical companies (Amgen, Genmab, Johnson and Johnson, MedImmune, Novartis, Progenics, Takeda) and contract research or manufacturing organizations (Baxter, Bayer, BSP Pharmaceuticals, Fujifilm/Diosynth, Lonza, Pierre Fabre Contract Manufacturing, Piramal, SAFC, SafeBridge).